Sonoma Pharmaceuticals (FRA:O8Z) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:O8Z Sonoma Pharmaceuticals Inc FRA:O8Z
34 GF Score
Price €2.72
GF Value €6.04
! 4 Warning Signs
View Full Analysis

What is Sonoma Pharmaceuticals Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:O8Z
34GF Score
Sonoma Pharmaceuticals Inc FRA:O8Z
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sonoma Pharmaceuticals (FRA:O8Z) Overvalued in 2026?

Based on GuruFocus' analysis, Sonoma Pharmaceuticals stock appears to be undervalued. The current stock price of €2.72 is trading 55% below its estimated GF Value™ of €6.04.

Key valuation signals for FRA:O8Z:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €6.04 vs. price of €2.72 (55% below fair value)
  • GF Score™: 34/100 with 4 warning signs

No single metric tells the full story. See the FRA:O8Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sonoma Pharmaceuticals Business Description

Other Exchanges SNOA:USA
Address 5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
34GF Score

Get the complete analysis for FRA:O8Z

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.72
Price
€6.04
GF Value